18 April 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
Oral Delivery
Update
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments and vaccines, is pleased to
provide a further positive update on its ongoing oral delivery
research work.
The Company, through its research
program with the University of Queensland, has undertaken further
testing, in vivo, to show
the successful delivery of a Nuvec® capsule into the intestine
where it has released its plasmid DNA payload to produce localised
protein expression. This work further demonstrates the potential of
Nuvec® as an oral delivery system for multiple nucleotide
payloads.
Specifically, in this experiment an
enterically coated capsule containing PEGylated Nuvec® loaded with
a plasmid DNA expressing ovalbumin was administered on day 0 and
subsequent capsules on day 3, day 6, day 9 and a booster capsule at
day 21. Protein expression was significantly higher than control
(DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25
which subsequently dropped away by day 36. In addition, a
significantly higher ovalbumin antibody response was measured at
day 36 in the PEGylated Nuvec® sample compared to
control.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"This work once more clearly shows that Nuvec® has the
potential to be developed as an oral delivery system for plasmid
DNA, mRNA or siRNA with many potential applications such as a
vaccination with plasmid DNA or to deliver a local product for
Irritable Bowel Disease or to treat colonic cancer among many
possible examples.
"We will continue to scope out the work needed to explore a
potential development program focusing on a specific oral
application and further news on this will be announced when a
program is identified. In the meantime, the University of
Queensland will continue its work as part of our ARC funded grant
with them."
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Engage with us directly at N4 Pharma
Investor Hub
To hear more, visit
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/oPBR0P
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia
Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to
partner with companies developing novel antigens in these fields to
use Nuvec® as the delivery vehicle for these antigens. As these
products progress through pre‐clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the Company
visit www.n4pharma.com or sign up at investors.n4pharma.com.